358 related articles for article (PubMed ID: 8688333)
1. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
2. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
3. A novel p53 mutation hotspot at codon 132 (AAG-->AGG) in human renal cancer.
Dahiya R; Deng G; Selph C; Carroll P; Presti J
Biochem Mol Biol Int; 1998 Feb; 44(2):407-15. PubMed ID: 9530523
[TBL] [Abstract][Full Text] [Related]
4. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
5. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
6. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor gene p53 mutations in human prostate cancer.
Kubota Y; Shuin T; Uemura H; Fujinami K; Miyamoto H; Torigoe S; Dobashi Y; Kitamura H; Iwasaki Y; Danenberg K
Prostate; 1995 Jul; 27(1):18-24. PubMed ID: 7603913
[TBL] [Abstract][Full Text] [Related]
8. Frequency and characterization of p53 mutations in clinically localized prostate cancer.
Hall MC; Navone NM; Troncoso P; Pollack A; Zagars GK; von Eschenbach AC; Conti CJ; Chung LW
Urology; 1995 Mar; 45(3):470-5. PubMed ID: 7879337
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
Mirchandani D; Zheng J; Miller GJ; Ghosh AK; Shibata DK; Cote RJ; Roy-Burman P
Am J Pathol; 1995 Jul; 147(1):92-101. PubMed ID: 7604888
[TBL] [Abstract][Full Text] [Related]
10. [Application of immunohistochemistry-laser microdissection-PCR technique in detecting p53 gene mutation in paraffin sections of gastric cancer].
Xu JH; Chen LR; Wang HJ; Yao LF
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):342-5. PubMed ID: 15363320
[TBL] [Abstract][Full Text] [Related]
11. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
12. p53 mutations and overexpression in locally advanced breast cancers.
Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F
Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984
[TBL] [Abstract][Full Text] [Related]
13. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.
Stapleton AM; Timme TL; Gousse AE; Li QF; Tobon AA; Kattan MW; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1997 Aug; 3(8):1389-97. PubMed ID: 9815823
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
15. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
18. Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India.
Karim S; Ali A
World J Gastroenterol; 2009 Mar; 15(11):1381-7. PubMed ID: 19294769
[TBL] [Abstract][Full Text] [Related]
19. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer.
Dinjens WN; van der Weiden MM; Schroeder FH; Bosman FT; Trapman J
Int J Cancer; 1994 Mar; 56(5):630-3. PubMed ID: 8314337
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.
Incognito LS; Cazares LH; Schellhammer PF; Kuban DA; Van Dyk EO; Moriarty RP; Wright GL; Somers KD
Int J Oncol; 2000 Oct; 17(4):761-9. PubMed ID: 10995889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
